Can what have we learnt about BCG vaccination in the last 20 years help us to design a better tuberculosis vaccine?
- PMID: 33583672
- PMCID: PMC8899334
- DOI: 10.1016/j.vaccine.2021.01.068
Can what have we learnt about BCG vaccination in the last 20 years help us to design a better tuberculosis vaccine?
Abstract
The BCG vaccine will, in 2021, have been in use for 100 years. Much remains to be understood, including the reasons for its variable efficacy against pulmonary tuberculosis in adults. This review will discuss what has been learnt about the BCG vaccine in the last two decades, and whether this new information can be exploited to improve its efficacy, by enhancing its ability to induce either antigen-specific and/or non-specific effects. Many factors affect both the immunogenicity of BCG and its protective efficacy, highlighting the challenges of working with a live vaccine in man, but new insights may enable us to exploit better what BCG can do.
Keywords: BCG; BCG vaccination; TB vaccines; Trained immunity; Tuberculosis.
Copyright © 2021. Published by Elsevier Ltd.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
-
- World Health Organization. WHO-UNICEF estimates of BCG coverage 2020. https://apps.who.int/immunization_monitoring/globalsummary/timeseries/ts... (accessed August 11, 2020).
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
